Navigation Links
Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
Date:8/20/2008

Moore Labriola LLP and The Schmidt Firm, LLP represent Virginia man who developed pancreatitis; FDA seeks more stringent warnings.

San Diego, CA (PRWEB) August 20, 2008 -- A Virginia man yesterday filed what is believed to be the first personal injury lawsuit stemming from injuries associated with the use of http://www.schmidtandclark.com/Byetta/ [Byetta]®, an injectable medication for diabetes. Victor Deleon alleges in a lawsuit filed in San Diego Superior Court (Case No. 37-2008-00090003-CU-PL-CTL) that the manufacturer of the drug, San Diego-based Amylin Pharmaceuticals, Inc., and the drug's co-marketer, Eli Lilly and Company, failed to adequately test and monitor the http://www.schmidtandclark.com/Byetta-Side-Effects/ [side effects of Byetta]®, and didn't warn doctors or patients of the risk of developing http://www.schmidtandclark.com/Byetta-Pancreatitis/ [pancreatitis]. Deleon was hospitalized in December of 2007 after developing the condition, which causes inflammation of the pancreas and can lead to bleeding and death.
        
Deleon's lawsuit comes two days after the Food and Drug Administration (FDA) announced that it has received six reports of hemorrhagic or necrotizing pancreatitis in patients taking Byetta® since October of 2007. Two of the six patients died. In a press release, the FDA said it is "working with the maker of http://moorelabriola.injuryhelpnetwork.com/byetta/ [Byetta]®" to add "stronger and more prominent warnings" to the product's label.

Deleon's lawsuit alleges that Amylin "failed to adequately warn prescribing physicians of the risk of pancreatitis, of measures needed to properly assess the appropriateness of prescribing the drug to certain categories of patients, and of measures doctors and patients could and should take to minimize the risk."

In the fall of 2007, Amylin agreed to add information about pancreatitis to the "precautions" section of the Byetta® label after the FDA reported 30 post-marketing reports of acute pancreatitis associated with the drug.

"It is pretty obvious that the label change in 2007 was not adequate," said Thomas M. Moore of http://moorelabriola.injuryhelpnetwork.com/ [Moore Labriola LLP] in Newport Beach, who jointly represents Mr. Deleon with Michael Schmidt of http://www.schmidtlaw.com/ [The Schmidt Firm, LLP] in Dallas, TX. "We believe that Amylin possessed data prior to the 2007 label revision that justified a stronger and more prominent warning than the precaution language that Amylin ultimately negotiated with FDA," Moore added.        

Contact:
Laci Thomas
The Schmidt Firm, LLP
Lthomas @ schmidtlaw.com
http://www.schmidtlaw.com
(866) 920-0753

###

Read the full story at http://www.prweb.com/releases/schmidt_law/Byetta/prweb1229814.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals Reports First Quarter Financial Results
2. Amylin Pharmaceuticals Reports 2007 Financial Results
3. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Amylin Pharmaceuticals to Webcast Conference Call
6. Amylin Pharmaceuticals to Webcast Third Quarter Results
7. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
8. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
9. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
10. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
11. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, a ... its 60-day free trial program for all of the company’s desktop riser products. ... truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced dual ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame ... (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking ... prescription drug plan (Part D) need to make changes during this period order for ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Va. , Dec. 2, 2016  The ... by the Academy of Managed Care Pharmacy (AMCP), ... organizations can better address the opioid addiction crisis, ... Assisted Therapies (MAT). ATAG,s newly released ... Improving Access to Naloxone," addresses many issues around ...
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
Breaking Medicine Technology: